Cancer Network | Colorectal Cancer
111 FOLLOWERS
Updates for oncologists treating colon and rectal cancer, including guidelines, therapies, and screening by colonoscopy, FIT, stool DNA, and fecal occult blood tests.
Cancer Network | Colorectal Cancer
1M ago
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test ..read more
Cancer Network | Colorectal Cancer
1M ago
The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer ..read more
Cancer Network | Colorectal Cancer
3M ago
Data from the BLUE-C trial support the approval of the Cologuard Plus test for colorectal cancer screening among at-risk individuals ..read more
Cancer Network | Colorectal Cancer
3M ago
The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC ..read more
Cancer Network | Colorectal Cancer
3M ago
The approval is based on results from the global phase 3 FRESCO-2 trial, which demonstrated improvement in OS in patients with refractory metastatic colorectal cancer ..read more
Cancer Network | Colorectal Cancer
3M ago
Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer ..read more
Cancer Network | Colorectal Cancer
4M ago
Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors ..read more
Cancer Network | Colorectal Cancer
4M ago
NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer ..read more
Cancer Network | Colorectal Cancer
5M ago
Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors ..read more
Cancer Network | Colorectal Cancer
5M ago
Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial ..read more